FORM 4

to Section 16. Form 4 or Form 5 obligations may continue. See

Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response: 0.								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Keyt Bruce					2. Issuer Name and Ticker or Trading Symbol IGM Biosciences, Inc. [IGMS]								heck all app Direc	,		10% (
(Last)	`	,	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 04/18/2023								X Officer (give file of Scientific Officer Chief Scientific Officer						
C/O IGM BIOSCIENCES, INC. 325 E. MIDDLEFIELD ROAD					4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line)						
(Street) MOUNT VIEW	'AIN CA	A 9	94043												X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	$ _{\Box}$	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.																	
		Table	e I - No	on-Deriva	tive \$	Secu	rities	Acc	quired	d, Dis	sposed of	, or B	enefici	ally Own	ed				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/					Execution Date		ate,	3. Transaction Code (Instr. 8) 4. Securities Acquii Disposed Of (D) (Instr. 5)					Securiti Benefic Owned	5. Amount of Securities Beneficially Owned Following Reported		: Direct	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) or (D)	Price	Transac	Transaction(s) (Instr. 3 and 4)			(11150: 4)	
Common Stock 04/18/20)23		A		21,126 ⁽¹⁾	A	\$0.0	138	138,080		D				
Common Stock												1,	1,013			See footnote ⁽²⁾			
		Та	ble II								osed of, convertib				d				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execu	eemed ution Date, h/Day/Year)	4. Transa Code (8)	(Instr. Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			6. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Exercisable Date			Amount of Securities		8. Price of Derivative Security (Instr. 5)	rivative derivativ curity Securitie		10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership (Instr. 4)	

Explanation of Responses:

Remarks:

/s/ Fred Schwarzer, by power of attorney

04/20/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{1.} These securities are restricted stock units (RSUs), granted pursuant to the election by the Reporting Person to receive RSUs in lieu of an earned cash bonus for performance in fiscal year 2022. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 100% of the RSUs shall vest in December 2023, provided that the Reporting Person remains a service provider through the vesting date.

^{2.} The shares are held directly by the Reporting Person's spouse.